Draft:Charles J. Ryan
| Submission declined on 8 October 2023 by Johannes Maximilian (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 30 September 2023 by Ldm1954 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Ldm1954 7 months ago. | |
| Submission declined on 20 July 2023 by Taking Out The Trash (talk). This submission reads more like an essay than an encyclopedia article. Submissions should summarise information in secondary, reliable sources and not contain opinions or original research. Please write about the topic from a neutral point of view in an encyclopedic manner. Declined by Taking Out The Trash 10 months ago. | |
| Submission declined on 20 July 2023 by Theroadislong (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Theroadislong 10 months ago. | |
Comment: There is too much unverified material here. For instance, the text claims 250 publications with 6 references, none of which back up the claims. A Google scholar page would help. It also contains fluff; the awards are very minor, and his marathon time is certainly not notable. Ldm1954 (talk) 09:23, 30 September 2023 (UTC)
- Comment: Reads like a resume. Taking Out The Trash (talk) 21:23, 20 July 2023 (UTC)
- Comment: perhaps suggest which three sources are the best? See WP:REFBOMB. Theroadislong (talk) 19:43, 20 July 2023 (UTC)
 | A major contributor to this article appears to have a close connection with its subject. (July 2023) |
Charles J. Ryan (born November 7, 1969) is an American physician-scientist, medical oncologist, and prostate cancer researcher. In August 2021, Ryan was announced as the new President and Chief Executive Officer of the Prostate Cancer Foundation.[1] In April 2018, Ryan was announced as Director of the Hematology, Oncology and Transplantation Division in the Department of Medicine at University of Minnesota and as Associate Director for Clinical Research and the B.J. Kennedy Chair in Clinical Medical Oncology in the institution’s Masonic Cancer Center, [2] [3] where he conducts research and sees patients through a clinical practice.
Ryan, while working at the University of California San Francisco (UCSF), was the principal cancer research investigator for the development of abiraterone acetate, sold under the brand name Zytiga[4] among others, as treatment for men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.[5][6] [7] The treatment is now considered standard of care therapy in multiple forms of advanced prostate cancer [8] that has been administered to hundreds of thousands of prostate cancer patients worldwide.[9]
Ryan has published more than 250 articles and chapters[10] in medical journals, including The New England Journal of Medicine [11], Journal of Clinical Oncology [12], and Cancer. He has also contributed chapters to several textbooks on prostate cancer and is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In [13] released in February 2018 by Benbella Publishing.[14]
Ryan also served as Co-Chair of the National Cancer Institute’s Prostate Cancer Task Force and as Leader of Advanced Prostate Cancer Care for the Alliance for Clinical Trials in Oncology.[15]
Early life and education[edit]
Ryan was born and raised in Appleton, WI, the youngest of four children.[16] Ryan’s father treated patients with many cancer types as a general oncologist in Appleton.[17] Ryan’s mother worked as an RN (registered nurse) at the local hospice in Appleton treating terminal cancer patients.[18]
Ryan attended Appleton West High School.[19] After high school, Ryan went on to earn a BA degree in History of Philosophy, magna cum laude, in 1991 from Marquette University in Milwaukee, WI where he was also a member of the academic honor society Phi Beta Kappa. After his undergraduate studies, Ryan attended the University of Wisconsin School of Medicine & Public Health where he earned his MD degree in 1996.[20]
Ryan trained at the University of Wisconsin Hospital and Clinics with a Residency in Internal Medicine until 1999, ultimately serving as Chief Resident in his final year in 2000, followed by a fellowship at Memorial Sloan-Kettering Cancer Center in Hematology and Medical Oncology from 2000 to 2003 in the institution’s Genitourinary Oncology Department.[21]
Medical practice and research career[edit]
University of California, San Francisco[edit]
In 2003, Ryan began treating genitourinary cancer patients as a Staff Physician in Oncology at UCSF Medical Center [22] and was named Assistant Clinical Professor of Medicine at the University of California, San Francisco in the Division of Hematology/Oncology.
In 2008, Ryan was named Associate Clinical Professor of Medicine. In 2010, Ryan was named Associate Clinical Professor of Medicine and Urology. In 2013, Ryan was named Professor of Clinical Medicine and Urology. In 2014, Ryan was announced as the Thomas Perkins Distinguished Professor in Cancer Research.[23] [24]
Ryan, while working at UCSF, was the principal cancer research investigator for the development of abiraterone acetate as treatment for men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.[25] [26] Ryan led the North American Phase I clinical trial [27] as well as the Phase II [28] [29] and Phase III [30] [31] studies that culminated in abiraterone acetate’s approval by the United States Food and Drug Administration on 28 April 2011 for mCRPC.[32]
Ryan was also the co-founder of the Supportive Therapy in Androgen Deprivation (STAND) program at UCSF, a program which seeks to integrate physical activity, nutrition, and emotional support for men receiving hormonal therapy for prostate cancer and their partners.[23]
University of Minnesota[edit]
In 2018, University of Minnesota Medical School announced Ryan as the new Director of the Hematology, Oncology and Transplantation Division in the Department of Medicine where he was also named Professor of Medicine.[2] He was also announced as Associate Director for Clinical Research in the Masonic Cancer Center and the B.J. Kennedy Chair in Clinical Medical Oncology.[3] Ryan began treating genitourinary cancer patients as a Staff Physician in Oncology at the University of Minnesota Medical Center.[33]
Prostate Cancer Foundation[edit]
When Ryan joined the Prostate Cancer Foundation in 2021[34], he launched the TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) initiative to support large-scale, multi-institutional team research projects addressing metastatic lethal prostate cancer, the most life-threatening form of prostate cancer.[35] The first four teams of researchers were announced in 2022, with up to $10 million in total funding for each team over a three-year period.[36]
Ryan also spearheaded the acquisition by PCF of Digital Science Press, Inc., (DSP).[37]
Other leadership and board positions[edit]
Ryan is a member of the medical advisory board of ZERO Prostate Cancer, a national nonprofit with the mission to end prostate cancer and help all who are impacted.[38]
Honors[edit]
In 2011 Ryan received both the Fellowship Program Mentor Award from the Division of Hematology/Oncology at UCSF and the Hematology/Oncology Mentor Award from the Department of Medicine at UCSF.[39]
Ryan also received the Commitment to Patient Care Award from the UCSF Symptom Management Service in 2008. In October 2016, Ryan was inducted into Appleton West High School’s alumni Hall of Fame.[40]
Personal life[edit]
Ryan is married to Jessica Leahy and has three children: two daughters, Catherine and Elise, and a son, Patrick. Ryan’s blood type is B-positive, a fact he brings up frequently in public forums as a demonstration of his view of the need of medical oncologists to remain upbeat in the face of lethal disease.[18] Ryan also speaks Spanish. [41]
References[edit]
- ^ "Prostate Cancer Foundation names genitourinary oncologist president, CEO". www.healio.com. Retrieved 2023-07-20.
- ^ a b eaton112 (2018-01-19). "Dr. Charles Ryan to Lead Medical School's Hematology, Oncology and Transplantation Division". Medical School. Retrieved 2023-07-20.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ a b "University of Minnesota Medical School Welcomes Charles Ryan". Targeted Oncology. 2018-01-30. Retrieved 2023-07-20.
- ^ "Zytiga - New Prostate Cancer Drug". www.medicalnewstoday.com. 2012-06-08. Retrieved 2023-07-21.
- ^ Media, Haymarket (2012-08-03). "Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer". Cancer Therapy Advisor. Retrieved 2023-07-21.
- ^ Ryan, Charles J.; Smith, Matthew R.; de Bono, Johann S.; Molina, Arturo; Logothetis, Christopher J.; de Souza, Paul; Fizazi, Karim; Mainwaring, Paul; Piulats, Josep M.; Ng, Siobhan; Carles, Joan; Mulders, Peter FA; Basch, Ethan; Small, Eric J.; Saad, Fred (2013). "Abiraterone in metastatic prostate cancer without previous chemotherapy". The New England Journal of Medicine. 368 (2): 138–148. doi:10.1056/nejmoa1209096. ISSN 0028-4793. PMC 3683570. PMID 23228172.
- ^ "Advanced Prostate Cancer Slows With New Drug | UC San Francisco". www.ucsf.edu. 2012-06-04. Retrieved 2023-07-21.
- ^ Kuznar, Wayne (2012-08-29). "Abiraterone Before Chemotherapy a Successful Strategy in Prostate Cancer".
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Appleton West inducts three into Hall of Fame". The Post-Crescent. Retrieved 2023-07-20.
- ^ "Google Scholar". scholar.google.com. Retrieved 2023-10-03.
- ^ Ryan, Charles J.; Smith, Matthew R.; de Bono, Johann S.; Molina, Arturo; Logothetis, Christopher J.; de Souza, Paul; Fizazi, Karim; Mainwaring, Paul; Piulats, Josep M.; Ng, Siobhan; Carles, Joan; Mulders, Peter F.A.; Basch, Ethan; Small, Eric J.; Saad, Fred (2013-01-10). "Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy". New England Journal of Medicine. 368 (2): 138–148. doi:10.1056/NEJMoa1209096. ISSN 0028-4793. PMC 3683570. PMID 23228172.
- ^ Stuyckens, Kim; Saad, Fred; Xu, Steven; Ryan, Charles J.; Smith, Matthew R.; Griffin, Thomas W.; Yu, Margaret K.; Vermeulen, An; Nandy, Partha; Poggesi, Italo (2014-02-01). "Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients". Journal of Clinical Oncology. 32 (4_suppl): 58. doi:10.1200/jco.2014.32.4_suppl.58. ISSN 0732-183X.
- ^ Ryan, Charles J. (2018-02-27). The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In. Dallas, TX: BenBella Books. ISBN 978-1-944648-56-5.
- ^ "The Virility Paradox". BenBella Books. Retrieved 2023-07-20.
- ^ "Charles J. Ryan". Grand Rounds in Urology. Retrieved 2023-07-20.
- ^ Prostatepedia (2018-03-26). "Dr. Charles Ryan: Why Oncology?". Prostatepedia. Retrieved 2023-07-20.
- ^ "@charlesryanmd". Twitter. Retrieved 2023-07-20.
- ^ a b bcampbell (2022-07-11). "Meet Chuck Ryan, M.D." Prostate Cancer Foundation. Retrieved 2023-07-20.
- ^ "West History". west.aasd.k12.wi.us. Retrieved 2023-07-20.
- ^ "NPI 1083672000 Dr. Charles J. Ryan in Minneapolis - Address, Medicare Status, and Contact Number". npino.com. Retrieved 2023-07-20.
- ^ "Dr. Charles Ryan, MD, Internal Medicine | San Francisco, CA | WebMD". doctor.webmd.com. Retrieved 2023-07-21.
- ^ "Charles Ryan | University of Minnesota Physicians". mphysicians.org. Retrieved 2023-07-21.
- ^ a b fable.co https://fable.co/author/charles-j-ryan-md. Retrieved 2023-07-20.
{{cite web}}: Missing or empty|title=(help) - ^ Lee, Stephanie M. (2014-05-20). "Tom Perkins gives UCSF $2.5 million to create professorship". SFGATE. Retrieved 2023-07-21.
- ^ Casey, Tim (August 2012). "Abiraterone Acetate in Patients with Advanced Prostate Cancer". hmpgloballearningnetwork.com. Retrieved 2023-07-21.
- ^ "Abiraterone and increased survival in metastatic prostate cancer". vivo.weill.cornell.edu. Retrieved 2023-07-21.
- ^ "A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer". academic.oup.com. 2017-03-17. Retrieved 2023-07-21.
- ^ Ryan, Charles J.; Shah, Shreya; Efstathiou, Eleni; Smith, Matthew R.; Taplin, Mary-Ellen; Bubley, Glenn J.; Logothetis, Christopher J.; Kheoh, Thian; Kilian, Christine; Haqq, Christopher M.; Molina, Arturo; Small, Eric J. (2011-07-15). "Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 17 (14): 4854–4861. doi:10.1158/1078-0432.CCR-11-0815. ISSN 1557-3265. PMC 3657705. PMID 21632851.
- ^ "Altmetric – Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response". aacr.altmetric.com. Retrieved 2023-07-21.
- ^ Media, Haymarket (2012-08-03). "Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer". Cancer Therapy Advisor. Retrieved 2023-07-20.
- ^ "Drug slows advanced prostate cancer - UPI.com". UPI. Retrieved 2023-07-20.
- ^ "Abiraterone: Current and FutureUse in Prostate Cancer – Hematology & Oncology". Retrieved 2023-07-21.
- ^ "Charles Ryan | University of Minnesota Physicians". mphysicians.org. Retrieved 2023-07-21.
- ^ Slater, Elias (2021-08-26). "The Prostate Cancer Foundation Appoints Charles J. Ryan, MD, as President and Chief Executive Officer". Prostate Cancer Foundation. Retrieved 2023-07-21.
- ^ Gallagher, Kathryn (2022-12-06). "The Prostate Cancer Foundation Announces Inaugural $30 Million TACTICAL Awards Program for Innovative Prostate Cancer Research". Prostate Cancer Foundation. Retrieved 2023-07-21.
- ^ jenlmat (2022-12-06). "Rogel researchers receive $4M through Prostate Cancer Foundation's inaugural TACTICAL awards program". Rogel Cancer Center | University of Michigan. Retrieved 2023-07-20.
- ^ Foundation, Prostate Cancer. "THE PROSTATE CANCER FOUNDATION ANNOUNCES THE ACQUISITION OF UROTODAY.COM AND DIGITAL SCIENCE PRESS". www.prnewswire.com. Retrieved 2023-07-21.
- ^ "Speaking out with Dr. Charles Ryan". ZERO Prostate Cancer. Retrieved 2023-07-21.
- ^ "Charles Ryan, MD Named the Marin Prostate Cancer Information and Support Group 2017 physician award". UCSF Department of Urology. Retrieved 2023-07-20.
- ^ "Q-Z". west.aasd.k12.wi.us. Retrieved 2023-07-20.
- ^ "Dr. Charles J. Ryan, MD | Internist in San Francisco, CA". Everyday Health-CARE. Retrieved 2023-07-20.